PL355098A1 - Związki imidazolowe jako inhibitory fosfodiesterazy VII - Google Patents

Związki imidazolowe jako inhibitory fosfodiesterazy VII

Info

Publication number
PL355098A1
PL355098A1 PL00355098A PL35509800A PL355098A1 PL 355098 A1 PL355098 A1 PL 355098A1 PL 00355098 A PL00355098 A PL 00355098A PL 35509800 A PL35509800 A PL 35509800A PL 355098 A1 PL355098 A1 PL 355098A1
Authority
PL
Poland
Prior art keywords
compounds used
imidazole compounds
phosphodiesterase vii
vii inhibitors
inhibitors
Prior art date
Application number
PL00355098A
Other languages
English (en)
Inventor
Hans Michael Eggenweiler
Rochus Jonas
Michael Wolf
Michael Gassen
Thomas Welge
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL355098A1 publication Critical patent/PL355098A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
PL00355098A 1999-11-13 2000-10-31 Związki imidazolowe jako inhibitory fosfodiesterazy VII PL355098A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19954707A DE19954707A1 (de) 1999-11-13 1999-11-13 Imidazolverbindungen als Phosphodiesterase VII-Hemmer
PCT/EP2000/010765 WO2001036425A2 (de) 1999-11-13 2000-10-31 Imidazolverbindungen als phosphodiesterase vii-hemmer

Publications (1)

Publication Number Publication Date
PL355098A1 true PL355098A1 (pl) 2004-04-05

Family

ID=7928973

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355098A PL355098A1 (pl) 1999-11-13 2000-10-31 Związki imidazolowe jako inhibitory fosfodiesterazy VII

Country Status (23)

Country Link
US (1) US6884800B1 (pl)
EP (1) EP1228073B1 (pl)
JP (1) JP4819272B2 (pl)
KR (1) KR20020049051A (pl)
CN (1) CN1390222A (pl)
AR (1) AR026421A1 (pl)
AT (1) ATE245653T1 (pl)
AU (1) AU775886B2 (pl)
BR (1) BR0015487A (pl)
CA (1) CA2391087A1 (pl)
CZ (1) CZ20021474A3 (pl)
DE (2) DE19954707A1 (pl)
DK (1) DK1228073T3 (pl)
ES (1) ES2200968T3 (pl)
HU (1) HUP0203422A3 (pl)
MX (1) MXPA02004728A (pl)
NO (1) NO20022232D0 (pl)
PL (1) PL355098A1 (pl)
PT (1) PT1228073E (pl)
RU (1) RU2002113759A (pl)
SK (1) SK6012002A3 (pl)
WO (1) WO2001036425A2 (pl)
ZA (1) ZA200204729B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN104758291B (zh) * 2007-03-27 2020-03-03 奥默罗斯公司 用于治疗运动障碍的pde7抑制剂的用途
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
DE102007047738A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR102385359B1 (ko) 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AU2018300091B2 (en) 2017-07-12 2023-06-22 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2919271A (en) 1957-12-05 1959-12-29 Smith Kline French Lab 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines
KR0167346B1 (ko) 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
US5318965A (en) * 1990-08-24 1994-06-07 Abbott Laboratories Quinobenzoxazine, antineoplastic agents
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity

Also Published As

Publication number Publication date
EP1228073A2 (de) 2002-08-07
RU2002113759A (ru) 2004-01-10
AU775886B2 (en) 2004-08-19
US6884800B1 (en) 2005-04-26
AU1390701A (en) 2001-05-30
HUP0203422A2 (hu) 2003-02-28
NO20022232L (no) 2002-05-10
AR026421A1 (es) 2003-02-12
JP2003514821A (ja) 2003-04-22
DE19954707A1 (de) 2001-05-17
DK1228073T3 (da) 2003-11-03
SK6012002A3 (en) 2002-09-10
MXPA02004728A (es) 2002-08-30
ZA200204729B (en) 2003-11-26
NO20022232D0 (no) 2002-05-10
WO2001036425A2 (de) 2001-05-25
ATE245653T1 (de) 2003-08-15
DE50003036D1 (de) 2003-08-28
EP1228073B1 (de) 2003-07-23
CN1390222A (zh) 2003-01-08
ES2200968T3 (es) 2004-03-16
WO2001036425A3 (de) 2002-01-10
PT1228073E (pt) 2003-12-31
CZ20021474A3 (cs) 2002-07-17
HUP0203422A3 (en) 2004-12-28
BR0015487A (pt) 2002-07-02
CA2391087A1 (en) 2001-05-25
KR20020049051A (ko) 2002-06-24
JP4819272B2 (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
HUP0202713A3 (en) Pteridinones as kinase inhibitors
GB2346877B (en) 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
EP1194152A4 (en) SIN KINASE INHIBITOR COMPOUNDS
EP1206260A4 (en) SRC-KINASE INHIBITING COMPOUNDS
PL355098A1 (pl) Związki imidazolowe jako inhibitory fosfodiesterazy VII
IL152872A0 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
HUP0303855A3 (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
HK1057702A1 (en) Triazole compounds useful as protein kinase inhibitors
GB9929973D0 (en) Heterocyclic compounds
HU9801711D0 (en) Use of substituted imidazolidin-2,4-dion compounds as analgetic
HK1049831A1 (zh) 作為磷酸二酯酶vii抑制劑的吡咯衍生物
PL355022A1 (pl) Pochodne imidazopirydyny jako inhibitory fosfodiesterazy VII
IL150114A0 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
PL351822A1 (en) Thienopyrimidines as phosphodiesterase inhibitors
PL355020A1 (pl) Pochodne imidazolu jako inhibitory fosfodiesterazy VII
AP2002002413A0 (en) Heterocyclic compounds inhibiting angiogenesi
SI1261588T1 (en) IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS
AU3324700A (en) Imidazole compounds
AUPQ515700A0 (en) Imidazole compounds
SI1226143T1 (en) Imidazopyridine derivatives used as phosphodiesterase vii inhibitors
SI1109560T1 (en) Compounds useful as aicarft inhibitors
SI1296981T1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
GB9915510D0 (en) Heterocyclic compounds
GB9916216D0 (en) Heterocyclic compounds
GB9916213D0 (en) Heterocyclic compounds